Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SARS-CoV-2-IN-13 (compound 5) is an analogue of niclosamide. SARS-CoV-2-IN-13 is more stable than niclosamide in human plasma and liver S9 enzymes assay. SARS-CoV-2-IN-13 can improve bioavailability and half-life when administered orally. SARS-CoV-2-IN-13 is a potent SARS-CoV-2 inhibitor with an IC 50 of 0.057 μM [1].
説明 | SARS-CoV-2-IN-13 (compound 5) is an analogue of niclosamide. SARS-CoV-2-IN-13 is more stable than niclosamide in human plasma and liver S9 enzymes assay. SARS-CoV-2-IN-13 can improve bioavailability and half-life when administered orally. SARS-CoV-2-IN-13 is a potent SARS-CoV-2 inhibitor with an IC 50 of 0.057 μM [1]. |
分子量 | 327.12 |
分子式 | C13H8Cl2N2O4 |
CAS No. | 56961-10-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 112.5 mg/mL (343.9 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SARS-CoV-2-IN-13 56961-10-5 Microbiology/Virology SARS-CoV Inhibitor inhibitor inhibit